Johnson & Johnson (NYSE:JNJ) Holdings Lessened by Davidson Trust Co.

Davidson Trust Co. decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 19,821 shares of the company’s stock after selling 923 shares during the quarter. Johnson & Johnson makes up about 2.0% of Davidson Trust Co.’s holdings, making the stock its 10th largest position. Davidson Trust Co.’s holdings in Johnson & Johnson were worth $3,107,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in JNJ. HTLF Bank acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth about $8,751,000. Colton Groome Financial Advisors LLC boosted its stake in shares of Johnson & Johnson by 32.6% during the fourth quarter. Colton Groome Financial Advisors LLC now owns 2,316 shares of the company’s stock worth $363,000 after buying an additional 570 shares during the period. Sterling Financial Planning Inc. boosted its stake in shares of Johnson & Johnson by 1.0% during the fourth quarter. Sterling Financial Planning Inc. now owns 10,383 shares of the company’s stock worth $1,627,000 after buying an additional 99 shares during the period. Fidelis Capital Partners LLC boosted its stake in shares of Johnson & Johnson by 30.5% during the fourth quarter. Fidelis Capital Partners LLC now owns 17,207 shares of the company’s stock worth $2,697,000 after buying an additional 4,026 shares during the period. Finally, Xponance Inc. boosted its stake in shares of Johnson & Johnson by 9.6% during the fourth quarter. Xponance Inc. now owns 344,420 shares of the company’s stock worth $53,984,000 after buying an additional 30,220 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 0.7 %

Shares of JNJ opened at $148.53 on Thursday. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.16 and a quick ratio of 0.91. The firm has a 50 day simple moving average of $155.69 and a 200-day simple moving average of $155.47. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $175.97. The stock has a market cap of $357.92 billion, a price-to-earnings ratio of 9.26, a price-to-earnings-growth ratio of 2.46 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.43%. The business had revenue of $21.38 billion during the quarter, compared to analysts’ expectations of $21.39 billion. During the same period last year, the company posted $2.68 EPS. The company’s revenue was up 2.3% on a year-over-year basis. Equities analysts forecast that Johnson & Johnson will post 10.65 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st will be given a $1.24 dividend. The ex-dividend date is Monday, May 20th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.34%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s payout ratio is currently 29.68%.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the sale, the executive vice president now owns 141,416 shares in the company, valued at approximately $22,099,078.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, EVP Jennifer L. Taubert sold 59,397 shares of the firm’s stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the sale, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder & Johnson Johnson sold 3,725 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now directly owns 4,099,575 shares in the company, valued at $105,810,030.75. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

JNJ has been the subject of a number of recent analyst reports. Morgan Stanley reduced their price objective on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 17th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. HSBC upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and raised their price objective for the company from $169.00 to $170.00 in a research report on Thursday, April 18th. Bank of America reduced their price objective on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research report on Monday, April 15th. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $175.86.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.